A regimen containing an experimental Merck drug suppressed the hepatitis C virus in most patients in a new clinical trial, and appears to be more potent than the company's Victrelis treatment.
WSJ.com: What's News US, Wall Street Journal
Sat, 11/10/2012 - 7:14am
A regimen containing an experimental Merck drug suppressed the hepatitis C virus in most patients in a new clinical trial, and appears to be more potent than the company's Victrelis treatment.